Table 1.
Characteristics of Included Studies
| Author | Year of publication | Study design | Primary outcome | Cannabinoidc | Type of cancer observed | Total No. of participants | Cannabinoid/Comparator (N)a | Population age, mean, y |
|---|---|---|---|---|---|---|---|---|
| Efird et al23 | 2004 | Observational retrospective | MPAGd | Unspecified | Glioma, NOS | 105005 | 60/9b | 51.9 |
| Blondin31 | 2018 | Observational prospective | Overall survival | Unspecified | Glioblastoma | 23 | 15/8b | 65 |
| Bar-Lev Schleider et al27 | 2018 | Observational prospective | Palliative effects | Unspecified | Multiple cancers | 2970 | 116/10b | 59.5e |
| Guzmán et al26 | 2006 | Pilot study | Survival | THC | Recurrent glioblastoma | 9 | 9/NA | 55.2 |
| Twelves et al30 | 2017 | Double-blind RCT | Safety and tolerance | CBD:THC | Recurrent glioblastoma | 21 | 12/9c | 58 |
Abbreviations: CBD, cannabidiol; MPAG, malignant primary adult-onset glioma; NA, not available; NOS, not otherwise specified; RCT, randomized controlled trial; THC, tetrahydrocannabinol.
aNumber of individuals with CNS tumors.
bComparator group received no intervention.
cComparator group received placebo.
dStudy evaluated risk of cannabis usage for developing MPAG.
eMean age of the overall population not brain/CNS specific.